Shares of Manulife Financial Corporation (NYSE:MFC) at the time when day-trade ended the stock finally dropped -0.51% to close at $19.61. Manulife Financial Corporation announced a Canadian public offering of Non-cumulative Rate Reset Class 1 Shares Series 25. Manulife will issue 10 million Series 25 Preferred Shares priced at $25 per share to raise gross proceeds of $250 million. The offering will be underwritten by a syndicate of investment dealers co-led by RBC Capital Markets, Scotiabank and TD Securities and is anticipated to qualify as Tier 1 capital for Manulife. Manulife has also granted the underwriters an option, exercisable in whole or in part at any time up to 48 hours prior to closing, to purchase up to an additional 2 million Series 25 Preferred Shares at the same offering price. The gross proceeds raised under the offering will be $300 million should this option be exercised in full. The expected closing date for the offering is February 20, 2018. Manulife intends to file a prospectus supplement to its December 15, 2017 base shelf prospectus in respect of this issue.
Holders of the Series 25 Preferred Shares will be entitled to receive a non-cumulative quarterly fixed dividend yielding 4.70 per cent annually, as and when declared by the Board of Directors of Manulife, for the initial period ending June 19, 2023. Thereafter, the dividend rate will be reset every five years at a rate equal to the 5-year Government of Canada bond yield plus 2.55 per cent.
Holders of Series 25 Preferred Shares will have the right, at their option, to convert their shares into Non-cumulative Floating Rate Class 1 Shares Series 26 (“Series 26 Preferred Shares”), subject to certain conditions, on June 19, 2023 and on June 19 every five years thereafter. Holders of the Series 26 Preferred Shares will be entitled to receive non-cumulative quarterly floating dividends, as and when declared by the Board of Directors of Manulife, at a rate equal to the three-month Government of Canada Treasury Bill yield plus 2.55 per cent.
The volatility tends to amount of risk or uncertainty about size of changes in a security’s value; a higher volatility denotes that a security’s value can potentially be spread out over a larger range of values. The price volatility of MFC was 3.28% for a week and 2.17% for a month as well as price volatility’s Average True Range for 14 days was 0.47. Shares price isolated negatively from its 50 days moving average with -6.75% and remote negatively from 200 days moving average with -1.13%.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) makeup itself as poignant stock, declined -0.34% to trade at $2.96. AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma (mRCC). The results were presentedat the 2018 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), in a poster presentation titled “Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC)” (Abstract 618).
The Phase 1/2 study has enrolled a total of 27 patients. The Phase 2 portion of the study (n=21) was designed to assess the safety, tolerability, and anti-tumor activity of the full dose and schedule of PO tivozanib (1.5 mg/QD for 21 days followed by a 7-day rest period), as established in the Phase 1 portion of the study (n=6), in combination with IV nivolumab (240 mg every 2 weeks). The combination was generally well tolerated. Treatment-related Grade 3/4 adverse events occurred in 44% of patients, the most common of which was hypertension.
Preliminary efficacy was assessed in 14 patients treated with the full dose and schedule of PO tivozanib in combination with IV nivolumab and enrolled at least 4 months prior to the data cutoff date. Of these, seven had received at least one prior systemic therapy. An objective response rate was observed in 64% of patients (partial responses), and a disease control rate (partial response + stable disease) was observed in 100% of patients. At the time of data collection, 11 of 14 evaluable patients remained on study.
“These preliminary data continue to support the rationale for choosing a high-specificity VEGF inhibitor TKI, such as tivozanib, in building upon the benefit of immune checkpoint therapy in renal cancer,” said Doctor Bernard Escudier, MD, ex-Chairman of the Genitourinary Oncology Committee, GustaveRoussy, and lead investigator of the study. “Combining VEGF TKIs and immune checkpoint inhibitors has been hampered by toxicity, potentially emerging with the use of other TKIs, while minimal off-target toxicities have been observed with tivozanib in this combination. These results open the possibility for triple-combination therapy using tivozanib, nivolumab and ipilimumab, an immune system activator targeting CTLA-4.”
The firm holds total outstanding shares are 118.30 million shares and floated shares were 117.56 million. As the returns are concern, return on equity was recorded 486.80% and firm decreased its return on investment -243.80% while its return on asset stayed at -200.30%.